# "The emerging role of capivasertib in breast cancer"

Source: https://onco.cc/key-papers/paper-capivasertib-breast-hr-positive-breast-2022/  
OnCo record `paper-capivasertib-breast-hr-positive-breast-2022` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Review on Capivasertib in HR-positive / HER2-negative breast cancer, in The Breast (2022), one of the most cited Europe PMC records with Capivasertib in its title.

## Summary

Over 50% of breast tumors harbor alterations in one or more genes of the phosphatidylinositol 3-kinase (PI3K) pathway including PIK3CA mutations (31%), PTEN loss (34%), PTEN mutations (5%) and AKT1 mutations (3%). While PI3K and mTOR inhibitors are already approved in advanced breast cancer, AKT inhibitors have been recently developed as a new therapeutic approach. Capivasertib (AZD5363) is a novel, selective ATP-competitive pan-AKT kinase inhibitor that exerts similar activity against the three AKT isoforms, AKT1, AKT2, and AKT3. Preclinical studies demonstrated efficacy of capivasertib in breast cancer cell lines as a single agent or in combination with anti-HER2 agents and endocrine treatment, especially in tumors with PIK3CA or MTOR alterations. Phase I/II studies demonstrated greater efficacy when capivasertib was co-administered with paclitaxel, fulvestrant in hormone receptor (HR)-positive, HER2-negative breast cancer or olaparib. The recommended phase II dose of capivasertib as monotherapy was 480 mg bid on a 4-days-on, 3-days-off dosing schedule. Toxicity profile proved to be manageable with hyperglycemia (20-24%), diarrhea (14-17%) and maculopapular rash (11-16%) being the most common grade ≥3 adverse events. Ongoing Phase III trials of capivasertib in combination with fulvestrant (CAPItello-291), CDK4/6 inhibitor palbociclib (CAPItello-292) and paclitaxel (CAPItello- 290) will better clarify the therapeutic role of capivasertib in breast cancer.

Indexed on Europe PMC as PubMed record 35398754 (DOI 10.1016/j.breast.2022.03.018). Its title names Capivasertib and its text names HR-positive / HER2-negative breast cancer; PubMed types it as a review (review-article, Review). It was matched automatically to the idea "Molecular-progression switching beyond ESR1" and no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: The Breast
- Year: 2022
- DOI: 10.1016/j.breast.2022.03.018
- Authors: Andrikopoulou A, Chatzinikolaou S, Panourgias E, et al.
- What it means: One of the most cited reviews Europe PMC returns for Capivasertib in HR-positive / HER2-negative breast cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
- Caveats: Matched by Capivasertib in the title and HR-positive / HER2-negative breast cancer in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.; A review summarises other studies; the primary reports it cites are the evidence.

## Sources

- Breast 2022: https://doi.org/10.1016/j.breast.2022.03.018
- PubMed: https://pubmed.ncbi.nlm.nih.gov/35398754/
- Europe PMC: https://europepmc.org/article/MED/35398754

## Connected records

- journals: [The Breast](https://onco.cc/journals/the-breast/)
- ideas: [Molecular-progression switching beyond ESR1](https://onco.cc/ideas/idea-ctdna-switch-generalised/)

---
JSON: https://onco.cc/api/v1/entities/paper-capivasertib-breast-hr-positive-breast-2022.json